Thoratec Corporation (NASDAQ: THOR) said that data released today from the Destination Therapy (DT) pivotal trial for the HeartMate II ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE